

Nicola Polverelli

List of Publications by Citations

Source: <https://exaly.com/author-pdf/621163/nicola-polverelli-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

130
papers

1,458
citations

22
h-index

34
g-index

144
ext. papers

1,969
ext. citations

3.9
avg, IF

4.08
L-index

#	Paper	IF	Citations
130	Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. <i>Haematologica</i> , 2013 , 98, 875-80	6.6	76
129	Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. <i>Blood Reviews</i> , 2017 , 31, 17-29	11.1	70
128	Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. <i>Journal of Thrombosis and Haemostasis</i> , 2014 , 12, 1266-73	15.4	62
127	Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. <i>American Journal of Hematology</i> , 2009 , 84, 215-20	7.1	56
126	Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. <i>American Journal of Hematology</i> , 2017 , 92, 37-41	7.1	53
125	Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. <i>Annals of Hematology</i> , 2011 , 90, 933-8	3	53
124	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020 , 126, 1243-1252	6.4	51
123	Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years. <i>American Journal of Hematology</i> , 2016 , 91, E267-72	7.1	50
122	Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. <i>Leukemia</i> , 2015 , 29, 1344-9	10.7	48
121	Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2021 , 385, 228-238	59.2	48
120	Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. <i>European Journal of Haematology</i> , 2017 , 98, 371-377	3.8	42
119	Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. <i>Cancer Medicine</i> , 2019 , 8, 2041-2055	4.8	40
118	Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. <i>American Journal of Hematology</i> , 2014 , 89, 306-9	7.1	39
117	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. <i>Hematological Oncology</i> , 2018 , 36, 561	1.3	38
116	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. <i>Oncotarget</i> , 2017 , 8, 79073-79086	3.3	38
115	Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia. <i>Annals of Hematology</i> , 2013 , 92, 67-78	3	31
114	Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease: An Italian Multicentric Retrospective Analysis on 94 Patients on Behalf of the Gruppo Italiano Trapianto di Midollo Osseo. <i>Transplantation</i> , 2016 , 100, e147-e155	1.8	30

113	A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. <i>British Journal of Haematology</i> , 2014 , 167, 541-6	4.5	29
112	JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients. <i>Leukemia and Lymphoma</i> , 2009 , 50, 247-53	1.9	28
111	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. <i>American Journal of Hematology</i> , 2020 , 95, 156-166	7.1	27
110	Mutations in and genes are associated with specific alterations of the immune system in myelofibrosis. <i>OncImmunity</i> , 2017 , 6, e1345402	7.2	25
109	Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge. <i>Annals of Hematology</i> , 2015 , 94, 519-20	3	24
108	Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients. <i>British Journal of Haematology</i> , 2012 , 156, 281-4	4.5	21
107	Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study. <i>Hematological Oncology</i> , 2018 , 36, 285-290	1.3	19
106	Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients. <i>American Journal of Hematology</i> , 2016 , 91, 318-21	7.1	19
105	Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study. <i>Blood</i> , 2020 , 136, 22-24	2.2	19
104	Feasibility of tumor-derived exosome enrichment in the onco-hematology leukemic model of chronic myeloid leukemia. <i>International Journal of Molecular Medicine</i> , 2019 , 44, 2133-2144	4.4	17
103	Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly. <i>Mediators of Inflammation</i> , 2016 , 2016, 5860657	4.3	17
102	The choice of second-line therapy in steroid-resistant immune thrombocytopenia: role of platelet kinetics in a single-centre long-term study. <i>American Journal of Hematology</i> , 2014 , 89, 1047-50	7.1	16
101	The CD47 pathway is deregulated in human immune thrombocytopenia. <i>Experimental Hematology</i> , 2011 , 39, 486-94	3.1	16
100	Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. <i>Haematologica</i> , 2010 , 95, 1038-40	6.6	16
99	Crucial factors of the inflammatory microenvironment (IL-1/TNF- α /TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study. <i>Oncotarget</i> , 2016 , 7, 43974-43988	3.3	16
98	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. <i>Blood Cancer Journal</i> , 2021 , 11, 4	7	16
97	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. <i>Leukemia Research</i> , 2018 , 74, 86-88	2.7	14
96	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. <i>Seminars in Hematology</i> , 2018 , 55, 218-255	4	13

95	Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms. <i>British Journal of Haematology</i> , 2013 , 161, 142-4	4.5	13
94	Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience. <i>Leukemia and Lymphoma</i> , 2009 , 50, 481-4	1.9	13
93	Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients. <i>Blood Advances</i> , 2019 , 3, 3196-3200	7.8	12
92	Multidimensional geriatric assessment for elderly hematological patients (≥80 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients. <i>Bone Marrow Transplantation</i> , 2020 , 55, 2224-2233	4.4	11
91	The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study. <i>Oncotarget</i> , 2017 , 8, 37239-37249	3.3	11
90	Sequential monitoring of lymphocyte subsets and of T-and-B cell neogenesis indexes to identify time-varying immunologic profiles in relation to graft-versus-host disease and relapse after allogeneic stem cell transplantation. <i>PLoS ONE</i> , 2017 , 12, e0175337	3.7	11
89	Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , 2021 , 95, 69-79	7.1	11
88	Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms. <i>Annals of Hematology</i> , 2015 , 94, 1585-7	3	10
87	MYH9-related thrombocytopenia and intracranial bleedings: a complex clinical/surgical management and review of the literature. <i>British Journal of Haematology</i> , 2015 , 170, 729-31	4.5	8
86	Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients. <i>Blood</i> , 2018 , 132, 4277-4277	2.2	8
85	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2021 , 193, 356-368	4.5	8
84	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. <i>Hematological Oncology</i> , 2020 , 38, 372-380	1.3	7
83	Digital PCR (Dpcr) a Step Forward to Detection and Quantification of Minimal Residual Disease (MRD) in Ph+/BCR-ABL1 Chronic Myeloid Leukemia (CML). <i>Journal of Molecular Biomarkers & Diagnosis</i> , 2017 , 08,	2	7
82	A Prognostic Model to Predict Survival After 6 Months of Ruxolitinib in Patients with Myelofibrosis.. <i>Blood Advances</i> , 2022 ,	7.8	7
81	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. <i>Cancer</i> , 2021 , 127, 2657-2665	6.4	7
80	RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients?. <i>Case Reports in Oncology</i> , 2020 , 13, 1263-1269	1	7
79	Seasonal Human Coronavirus Respiratory Tract Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Infectious Diseases</i> , 2021 , 223, 1564-1575	7	7
78	Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis. <i>Annals of Hematology</i> , 2015 , 94, 339-41	3	6

77	Comparison of JAK2 -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology. <i>Hematological Oncology</i> , 2018 , 36, 269-275	1.3	6
76	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. <i>British Journal of Haematology</i> , 2018 , 183, 35-46	4.5	6
75	Exosomes in Chronic Myeloid Leukemia: Are We Reading a New Reliable Message?. <i>Acta Haematologica</i> , 2020 , 143, 509-510	2.7	6
74	Bacterial Blood Stream Infections Negatively Impact on Outcome of Patients Treated with Allogeneic Stem Cell Transplantation: 6 Years Single-Centre Experience. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017 , 9, e2017036	3.2	6
73	Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly. <i>British Journal of Haematology</i> , 2016 , 174, 160-2	4.5	6
72	Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years. <i>British Journal of Haematology</i> , 2012 , 156, 676-9	4.5	5
71	CMV Management with Specific Immunoglobulins: A Multicentric Retrospective Analysis on 92 Allografted Patients. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019 , 11, e2019048	3.2	4
70	Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study). <i>British Journal of Haematology</i> , 2019 , 186, e123-e126	4.5	4
69	Circulating CD4+CD25-Foxp3+ cells are increased in patients with immune thrombocytopenia. <i>Immunology Letters</i> , 2015 , 166, 63-4	4.1	4
68	Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2700-2705	1.9	4
67	Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis. <i>Blood</i> , 2016 , 128, 1128-1128	2.2	4
66	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. <i>Annals of Hematology</i> , 2019 , 98, 889-896	3	4
65	A Systematic Review of the Literature and Perspectives on the Role of Biomarkers in the Management of Malnutrition After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2020 , 11, 535890	8.4	4
64	Case Report: Late Onset of Myelodysplastic Syndrome From Donor Progenitor Cells After Allogeneic Stem Cell Transplantation. Which Lessons Can We Draw From the Reported Case?. <i>Frontiers in Oncology</i> , 2020 , 10, 564521	5.3	3
63	: A Candidate Gene for Predisposition to "Blend Pedigrees"? A Case Report from the NEXT-Family Clinical Trial. <i>Case Reports in Hematology</i> , 2020 , 2020, 2795656	0.7	3
62	A case report of acute myeloid leukemia and neurofibromatosis 1. <i>Hematology Reports</i> , 2013 , 5, 28-9	0.9	3
61	Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. <i>Hematological Oncology</i> , 2021 , 39, 409-418	1.3	3
60	Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey). <i>Bone Marrow Transplantation</i> , 2021 , 56, 2272-2275	4.4	3

59	Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. <i>Leukemia</i> , 2021 , 35, 2445-2459	10.7	3
58	dsDNA from extracellular vesicles (EVs) in adult AML. <i>Annals of Hematology</i> , 2021 , 100, 1355-1356	3	3
57	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. <i>Hematological Oncology</i> , 2019 , 37, 418-423	1.3	2
56	Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency. <i>Hematology Reports</i> , 2012 , 4, e10	0.9	2
55	Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.. <i>British Journal of Haematology</i> , 2022 ,	4.5	2
54	Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF). <i>Blood</i> , 2019 , 134, 1684-1684	2.2	2
53	Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience. <i>Blood</i> , 2019 , 134, 839-839	2.2	2
52	Crucial Factors of the Inflammatory Microenvironment Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating Survival and Inhibiting Proliferation of CD34+ stem/Progenitor Cells. <i>Blood</i> , 2014 , 124, 3220-3220	2.2	2
51	Risk Factors for Infections in Myelofibrosis: Role of Disease Status and Treatment. A Study on 507 Patients. <i>Blood</i> , 2015 , 126, 1606-1606	2.2	2
50	Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis. <i>Blood</i> , 2016 , 128, 4251-4251	2.2	2
49	S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY. <i>HemaSphere</i> , 2019 , 3, 396-397	0.3	2
48	Severe Acute Respiratory Syndrome Coronavirus-2 Pandemia: Facts and Perspectives in a Bone Marrow Transplant Unit. <i>Frontiers in Oncology</i> , 2020 , 10, 1626	5.3	2
47	Minimal residual disease monitoring in acute myeloid leukaemia: are we ready to move from bone marrow to peripheral blood?. <i>British Journal of Haematology</i> , 2020 , 190, 135-136	4.5	1
46	Update on the treatment of Ph-negative myeloproliferative neoplasms. <i>International Journal of Hematologic Oncology</i> , 2013 , 2, 251-262	1	1
45	Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach. <i>Blood</i> , 2018 , 132, 4387-4387	2.2	1
44	Comparative Monitoring of Minimal Residual Disease (MRD) By RT-Quantitative (RT-qPCR) and Digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) Patients Treated with TKIs for Recognition of Stable Deep Molecular Response (DMR) and Identification of Best Candidates to TKIs Treatment Discontinuation. <i>Blood</i> , 2018 , 132, 3012-3012	2.2	1
43	Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasms. A Study Of The IWG-MRT In 475 Subjects. <i>Blood</i> , 2013 , 122, 1582-1582	2.2	1
42	Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasms: A Study of the AGIMM & IWG-MRT Groups in 519 Subjects. <i>Blood</i> , 2014 , 124, 3163-3163	2.2	1

41	Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study. <i>Blood Research</i> , 2020 , 55, 139-145	1.4	1
40	Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) in Myelofibrosis Patients Treated with Ruxolitinib: A Multi-Center Experience. <i>Blood</i> , 2018 , 132, 4303-4303	2.2	1
39	Clinical Outcomes Under Hydroxyurea and Impact of ELN Responses in Patients with Polycythemia Vera: A PV-NET Real World Study. <i>Blood</i> , 2019 , 134, 4174-4174	2.2	1
38	Advances in CMV Management: A Single Center Real-Life Experience. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 534268	5.7	1
37	Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms. <i>Cells</i> , 2021 , 10,	7.9	1
36	Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner?. <i>Case Reports in Hematology</i> , 2019 , 2019, 3914828	0.7	0
35	Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival. <i>Blood</i> , 2020 , 136, 17-18	2.2	0
34	Multidimensional Geriatric Assessment for Elderly Patients (≥80 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients. <i>Blood</i> , 2019 , 134, 41-41	2.2	0
33	GITMO REGISTRY STUDY ON ALLOGENEIC TRANSPLANTATION IN PATIENTS AGED OVER 60 FROM 2000 TO 2017. IMPROVEMENTS AND CRITICISMS. <i>Transplantation and Cellular Therapy</i> , 2021 , 28, 96.e1-96.e1		0
32	Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study. <i>Cancer Medicine</i> , 2021 , 10, 1726-1737	4.8	0
31	Clinical Care of Hematological Patients in a Bone Marrow Transplant Unit: Do Human Resources Influence Infection Incidence?. <i>Infection Control and Hospital Epidemiology</i> , 2017 , 38, 1131-1132	2	
30	Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome. <i>Blood</i> , 2020 , 136, 49-50	2.2	
29	First Line Treatment with Hydroxyurea in Patients with Polycythemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria. <i>Blood</i> , 2020 , 136, 43-44	2.2	
28	Overall Survival Improvement Following ALLO-SCT in Patients Older THAN 60 YEARS: A Gruppo Italiano Trapianto DI Midollo Osseo (GITMO) Registry Study. <i>Blood</i> , 2021 , 138, 1786-1786	2.2	
27	Peripheral Blasts Are Associated with Response to Ruxolitinib and Outcome in Patients with Chronic-Phase Myelofibrosis. <i>Blood</i> , 2021 , 138, 3624-3624	2.2	
26	Presentation and Outcome of 199 Patients with 2016 Who Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib. <i>Blood</i> , 2018 , 132, 3052-3052	2.2	
25	ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience. <i>Blood</i> , 2018 , 132, 3381-3381	2.2	
24	First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response. <i>Blood</i> , 2018 , 132, 4251-4251	2.2	

- 23 PS1540 MULTIPARAMETRIC PREDICTIVE SCORE FOR GRAFT VERSUS HOST DISEASE (GVHD) IN PATIENTS SUBMITTED TO ALLOGENEIC STEM CELLS TRANSPLANTATION (SCT). *HemaSphere*, **2019**, 3, 711 0.3
- 22 PB2269 PARENTERAL NUTRITION AND ACUTE GVHD IN HEMATOPOIETIC STEM CELLS TRANSPLANTATION: A PROSPECTIVE OBSERVATIONAL COHORT STUDY. *HemaSphere*, **2019**, 3, 1014-1015⁹³
- 21 Post Induction and Post Consolidation Measurable/Minimal Residual Disease Predict Relapse in NPM-1 Positive AML. Outcome of Treatment Relapse. a Single Center Experience. *Blood*, **2019**, 134, 2695-2695²
- 20 Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. *Blood*, **2019**, 134, 4166-4166 2.2
- 19 Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study. *Blood*, **2019**, 134, 4184-4184 2.2
- 18 Initial Therapeutic Approach and Relationship with Clinical and Biological Characteristics at Diagnosis in 2418 Patients of the Registro Italiano Trombocitemie (RIT). *Blood*, **2014**, 124, 3196-3196 2.2
- 17 Key Immune Cell Subsets Are Dysregulated in Patients with Myelofibrosis. *Blood*, **2014**, 124, 5580-5580 2.2
- 16 Mutations and Long-Term Outcome of 217 Young Patients with Essential Thrombocythemia or Early Primary Myelofibrosis. *Blood*, **2014**, 124, 3190-3190 2.2
- 15 JAK2V617F-Positive Patients with Essential Thrombocythemia or Early Primary Myelofibrosis: The Impact of Histological Diagnosis on Outcome. *Blood*, **2015**, 126, 1614-1614 2.2
- 14 Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells. *Blood*, **2015**, 126, 4094-4094 2.2
- 13 Impact of Comorbidities and Body Mass Index in Myelofibrosis Patients Treated with Ruxolitinib: A Retrospective Analysis. *Blood*, **2016**, 128, 5464-5464 2.2
- 12 Incidence and Outcome of Bacterial Blood Stream Infections in Allografted Patients: Rethinking the Role of Fluoroquinolone Prophylaxis. *Blood*, **2016**, 128, 2223-2223 2.2
- 11 Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR). *Blood*, **2016**, 128, 3096-3096 2.2
- 10 Comparative Study on Fresenius-ATG Versus Thymoglobuline-ATG for the Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation from Matched Unrelated Donor: A Single Center Experience on 76 Patients. *Blood*, **2016**, 128, 4601-4601 2.2
- 9 Characterization of the CD47/SIRP-Alpha System in Patients with Immune Thrombocytopenia.. *Blood*, **2009**, 114, 1309-1309 2.2
- 8 Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience.. *Blood*, **2009**, 114, 2027-2027 2.2
- 7 Impaired Interaction Between Regulatory T Cells and Dendritic Cells in Immune Thrombocytopenia.. *Blood*, **2009**, 114, 3511-3511 2.2
- 6 Decreased Expression of Indoleamine 2,3-Dioxygenase 1 (IDO 1) in Dendritic Cells From Patients with Immune Thrombocytopenia (ITP) Correlates with Impaired Regulatory T Cells Development. *Blood*, **2010**, 116, 2770-2770 2.2

- 5 The CD47 Pathway Is Deregulated In Human Immune Thrombocytopenia (ITP).. *Blood*, **2010**, 116, 3776-3776
- 4 Clonality and Phenotype in Splens From Patients with Primary Immune Thrombocytopenia,. *Blood*, **2011**, 118, 3291-3291 2.2
- 3 Decreased Expression of Indoleamine 2,3-Dioxygenase 1 in Dendritic Cells From Patients with Immune Thrombocytopenia Induces Impaired Regulatory T-Cell Development. *Blood*, **2011**, 118, 696-696^{2.2}
- 2 Thrombosis History and Relationship With Low Thrombocytosis, Leukocytosis, and Other Characteristics At Diagnosis In 977 Essential Thrombocythemia Patients A Multivariate Analysis Of The Registro Italiano Trombocitemie (RIT). *Blood*, **2013**, 122, 2829-2829 2.2
- 1 Successful hematopoietic stem cell transplantation for complete CTLA-4 haploinsufficiency due to a de novo monoallelic 2q33.2-2q33.3 deletion. *Clinical Immunology*, **2020**, 220, 108589 9